First Tracks Biotherapeutics (TRAX) stock
TRAX's Quality Score fell 1 point on Mon, Oct 5, to -3. Its volume eased back to normal.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Why TRAX scores -3
PoorChoppy, 0 of 14 checks firingWhat the Quality Score means
- −1Dilution 21.5% more shares outstanding than a year ago
- −2Volatility moves 8.9% a day with no profit or positive free cash flow over four quarters on file
What's next
Expected to report Thu Nov 5, after the close
After its last 2 reports it closed -5.8% on average, higher 0 of 2 times.
What would turn TRAX's score around: 4 things, for Pro members
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
Nothing is firing on TRAX right now
One per group is shown here.
Also on the chart
- RSI 1436.0
- MACD (12, 26, 9)Below signal
- 50-day average$41.37
- ADX 1414.9
- Support$15.69
- Resistance$42.24
- Bollinger Bands (20, 2)Inside
- Volume0.9x
How TRAX ranks in Biotech
TRAX is #221 of 300 by Quality Score. The top three are shown with their scores, and more by name.
ONC8/1420
RGEN8/1420
CORT8/1418
TLXOpen for its score
TNGXOpen for its score
TRDAOpen for its score
TSHAOpen for its score
TRAX0/14-3
When does TRAX report earnings, and what happens after?
Expected to report Thu Nov 5, after the close (in 30 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 12, 2026After close | After close | +0.0% | -4.5% | -1.4% |
| May 14, 2026After close | After close | -1.1% | -6.9% | -7.7% |
Who is trading TRAX
TRAX insider trades
One insider sold $1.8M across 1 filing in the last 6 months. No open-market buys on record. The newest:
About First Tracks Biotherapeutics
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
Pro members see every line of every stock's score.
- Real-time prices, no delay
- Every line of TRAX's score, with the points and the reason
- All 14 checks on TRAX and on all 3,243 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on TRAX
Straight Answers
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.